15th Annual Highlights of ASCO Recorded Session
This program is designed for physicians, PAs, nurse practitioners, registered nurses, medical staff and pharmacists in Wisconsin and neighboring states wanting to learn about the latest updates in cancer treatment. The conference is designed to review the current clinical updates from the American Society of Clinical Oncology (ASCO) annual meeting. The conference will educate regarding practice-changing findings presented at ASCO 2022.
This course is intended for physicians, PAs, nurse practitioners, registered nurses, medical staff and pharmacists in Wisconsin and neighboring states wanting to learn about the latest updates in cancer treatment.
At the end of this session, learners should be able to:
- Review highlights of the advances in clinical and translational research presented at the 2022 ASCO® annual meeting
- Identify emerging trends and strategies designed to improve the quality of symptom management and survivorship care
- Evaluate tools and resources in specific areas of cancer management that can be used to achieve effective cancer care delivery and improve the patient experience
Michael Mullane, MD; Medical Oncologist, Advocate Aurora Health. Medical Director, Hereditary Cancer Prevention and Management Center; Advocate Aurora Health
James Weese, MD, FACS; Vice President, Cancer Service Line and Clinical Adjunct Professor of Surgery UW School of Medicine & Public Health, Aurora Cancer Care; Advocate Aurora Health
Toni Choueiri, MD; Director, Lank Center for Genitourinary Oncology Department of Medical Oncology, Dana-Farber Cancer Institute; Co-Leader, Kidney Cancer Program; Dana-Farber/Harvard Cancer Center; Jerome and Nancy Kohlberg Professor of Medicine; Harvard Medical School
Lawrence Einhorn, MD; Livestrong Foundation Professor of Oncology Distinguished Professor of Medicine, Department of Medicine, Indiana University
Edward James, MD; Gastrointestinal Oncology- Advocate Medical Group/ Lutheran General Hospital; Cancer Liaison Physician, Advocate Aurora Health, Central Chicagoland Lecturer - Rosalind Franklin Univ. School of Medicine and Science, North Chicago, IL
Brad Kahl, MD; Professor, Department of Medicine, Oncology Division Medical Oncology; Director, Lymphoma Program, Washington University
Rubina Qamar, MD Medical Oncologist, Aurora Cancer Care, Advocate Aurora Health
Corey Shamah, MD Medical Director, Hematology / Oncology, Advocate Aurora Health, Wisconsin
Nataliya Uboha, MD, PhD; Faculty Leader for Cancer Therapy Discovery & Development/Phase I Program; Associate Professor, Department of Medicine, Section of Hematology & Oncology University of Wisconsin
Kari Braun Wisinski, MD; Professor of Medicine; Chief of the Division of Hematology, Medical Oncology and Palliative Care; Co-Lead, Breast Cancer Disease Oriented Team; Associate Director for Clinical Research, Univ. of Wisconsin Carbone Cancer Ctr.
The following faculty speakers and/or planning committee members have disclosed the following:
Name of Ineligible Companies
Nature of Relationship
Toni Choueiri, MD
AstraZeneca PLC, Bristol Myers Squibb, Eisai Inc.
Committees: Consultancy regarding therapies for Kidney Cancer/GU Cancers
Consultancy fees, advisory boards, payments for clinical trials (personal and institutional)
|Lawrence Einhorn, MD||Amgen||Stock|
|Brad Kahl, MD|
1. Genentech, ADC Therapeutics, Abbvie, AstraZeneca, BeiGene, Pharmacyclics, Celgene/BMS, TG Therapeutics, Hutchmed, MEI, MTEM, Kite, Epizyme, Takeda, Genmab, Incyte, Lilly
2. Genentech, ADC Therapeutics, Abbvie, AstraZeneca, BeiGene
2. Research Funding
|Nataliya Uboha, MD|
1. Incyte, AstraZeneca, Pfizer, Boston Gene,
2. Ipsen, Taiho & EMD Serono
3. Natera, Inc & Exact Sciences
1. Ad Board
2. Research Funding
3. Long Position Holdings
|Kari Braun Wisinski, MD|
1. Advisory Board, Other Consulting, Researcher (grant to intention), Contracted Research
The other planner(s) and speaker(s) have indicated that there are no relevant financial relationships with any ineligible companies to disclose. All of the relevant financial relationships listed for [this individual/these individuals] have been mitigated.
In support of improving patient care, Advocate Aurora Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
American Medical Association (AMA)
Advocate Aurora Health designates this live activity for a maximum of 2.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 2.50 AMA PRA Category 1 Credit™Aurora Health Care is accredited by the Wisconsin Medical Society to provide continuing medical education for physicians. Aurora Health Care designates this activity for a maximum of 2.50 AMA PRA Category 1 Credit(s)TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 2.50 AttendanceAttendance Credit
- 2.50 Approved AMA PRA Category 1 Credit™
Click “Take Course” to register for this program.
Contact the Advocate Aurora Health CME Office at email@example.com if you have any questions or need assistance.